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Abstract: 
Background  
Increasing use of BRCA1/2 testing for tailoring cancer treatment and 
extension of testing to tumour tissue for somatic mutation is moving 
BRCA1/2 mutation screening from a primarily prevention arena delivered 
by specialist genetic services into mainstream oncology practice. A 
considerable number of gene tests will identify rare variants where clinical 
significance cannot be inferred from sequence information alone. The 
proportion of Variants of Uncertain clinical Significance (VUS) is likely to 
grow with lower thresholds for testing and laboratory providers with less 
experience of BRCA. Most VUS will not be associated with a high risk of 
cancer but a misinterpreted VUS has the potential to lead to 
mismanagement of both the patient and their relatives.  
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Design  
Members of the Clinical Working Group of  ENIGMA (Evidence-based 
Network for the Interpretation of Germline Mutant Alleles) global 
consortium (www.enigmaconsortium.org) observed wide variation in 
practices in reporting, disclosure and clinical management of patients with 
a VUS. Examples from current clinical practice are presented and discussed 
to illustrate potential pitfalls, explore factors contributing to 
misinterpretation, and propose approaches to improving clarity.  
 
Results and conclusion  
Clinicians, patients and their relatives would all benefit from an improved 
level of genetic literacy. Genetic laboratories working with clinical 
geneticists need to agree on a clinically clear and uniform format for 
reporting BRCA test results to non-geneticists.  An international consortium 
of experts, collecting and integrating all available lines of evidence and 
classifying variants according to an internationally recognized system will 
facilitate reclassification of variants for clinical use.  
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Abstract 
Background 
Increasing use of BRCA1/2 testing for tailoring cancer treatment and extension of testing 
to tumour tissue for somatic mutation is moving BRCA1/2 mutation screening from a 
primarily prevention arena delivered by specialist genetic services into mainstream oncology 
practice. A considerable number of gene tests will identify rare variants where clinical 
significance cannot be inferred from sequence information alone. The proportion of Variants 
of Uncertain clinical Significance (VUS) is likely to grow with lower thresholds for testing 
and laboratory providers with less experience of BRCA. Most VUS will not be associated 
with a high risk of cancer but a misinterpreted VUS has the potential to lead to 
mismanagement of both the patient and their relatives. 
  
Design 
Members of the Clinical Working Group of  ENIGMA (Evidence-based Network for 
the Interpretation of Germline Mutant Alleles) global consortium 
(www.enigmaconsortium.org) observed wide variation in practices in reporting, disclosure 
and clinical management of patients with a VUS. Examples from current clinical practice are 
presented and discussed to illustrate potential pitfalls, explore factors contributing to 
misinterpretation, and propose approaches to improving clarity. 
 
Results and conclusion 
Clinicians, patients and their relatives would all benefit from an improved level of 
genetic literacy. Genetic laboratories working with clinical geneticists need to agree on a 
clinically clear and uniform format for reporting BRCA test results to non-geneticists.  An 
international consortium of experts, collecting and integrating all available lines of evidence 
and classifying variants according to an internationally recognized system will facilitate 
reclassification of variants for clinical use.  
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Introduction  
 Germline inactivating variants in the tumor suppressor genes BRCA1 and BRCA2 
confer high life time risks of breast cancer, ovarian cancer and less frequently also other 
cancers[1[. These pathogenic variants are conventionally called ‘mutations’ or ‘deleterious 
variants’ in BRCA genetic testing parlance and the term pathogenic variant is used here for 
the sake of precision. Pathogenic variants in either gene confer a high lifetime risk of 
developing ovarian or (another) primary breast cancer in female carriers but they explain only 
about 20% of familial breast cancer[2[. The more cancers, the younger the onset and the 
admixture of ovarian with breast cancer amongst relatives all increase the chance that a 
familial cluster is due to a BRCA gene mutation but nonetheless most familial clusters of 
breast cancer are not due to an inherited mutation in BRCA1 or BRCA2.  In addition to 
familial clusters BRCA mutations account for over 10% of patients with early onset triple 
negative breast cancer and over 10% of women with non-mucinous ovarian cancer with no 
family history[3,4[.  Female carriers with pathogenic variants can make informed decisions 
about prophylactic surgery or intensified screening programs. High profile media coverage 
increases patient expectations from genetic testing[5,6[. The indications for germline genetic 
testing for BRCA1 and BRCA2 are further increasing to include directing cancer 
chemotherapy, novel targeted treatments and informing choices about the extent of 
therapeutic surgery[7-9[. Germline genetic testing for BRCA1 and BRCA2 for cancer risk 
prediction and management is routinely delivered by clinical genetics professionals but 
increasing demand is overwhelming the current delivery model with insufficient capacity 
amongst trained geneticists and genetic counsellor. Safe integration of genetic counselling 
and testing for HBOC into mainstream oncology is an ongoing challenge. Challenges exist at 
many levels but key are genetic literacy and genetic test outcome interpretation and reporting. 
 
Variability between individuals’ genetic code is common within the general population and 
between individuals of different ethnic background and this intrinsic variability can lead to 
difficulties in interpreting some types of sequence change (see supplementary figure F1 for 
more information). Variants of uncertain clinical significance (VUS) represent a particular 
challenge since the clinical significance cannot be inferred from sequence information alone. 
Mis-interpretation of VUS can lead to real clinical harms for both patients and families [10-
12[.Furthermore terms used in genetic test clinical reports vary (see supplementary table T1). 
Up to 20% of BRCA1/2 tests will report genetic variants of uncertain clinical significance 
(VUS) but in a well characterised ethnic population the proportion may drop to 5% or 
less[13-15[. The ENIGMA consortium has received over 6,000 submissions of unique VUS, 
identified in over 13,000 families from over 17 countries[16[. Laboratories following generic 
reporting rules and with limited BRCA specific experience, may report more significance to 
variants in BRCA genes than is supported when multiple lines of evidence are taken into 
account[17[. The percentage of gene-tests resulting in a VUS is expected to increase when 
the extent of sequencing increases to include untranslated and deeper intronic regions and 
when tumour testing is offered. We restrict examples in this paper to the BRCA genes tested 
in blood samples.  
 
Members of the Evidence-based Network for the Interpretation of Germline Mutant Alleles 
(ENIGMA) consortium’s Clinical Working Group have collated real case scenarios from 
clinical practice to illustrate the pitfalls that can arise after a VUS test result and suggest some 
strategies to mitigate this risk. Clinicians who are requesting BRCA tests need to consider 
these issues when using BRCA test results in the management of patients and their families. 
 
I. The VUS report: why are VUS difficult to classify?   
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I-1- Pitfalls associated with variability in the information content of genetic test reports 
 Based on the experience of representatives from 17 countries, it is clear that there is 
currently no internationally accepted standard for BRCA testing reporting (supplementary 
table T1), and no agreed consistent classification system: some laboratories report variants 
without interpretation, some use a narrative approach and some use locally developed 
guidelines or published schemes[18,19[. For some types of BRCA gene variants, additional 
evidence may be essential before a variant can be clearly classified. Different lines of 
evidence may appear to conflict, so an integrated estimation of probability taking all available 
evidence into account is essential to reach a final classification for many variants[20,21[]. 
 
I-1a-Multiple lines of evidence may be required to establish pathogenicity 
 Software packages are available to help interpret genetic variants, each with strengths 
and weaknesses (supplementary table T2). Understanding of how the multiple functions of 
the BRCA1 and BRCA2 proteins relate to cancer predisposition is limited and few validated 
functional assays are available[22[]. The interpretation of functional studies is often 
technically complex and results may not be calibrated against clinical parameters in order to 
give measures of sensitivity and specificity. A major breakthrough in the field of BRCA 
variant classification has been the development of a multifactorial likelihood classification 
model[20,23[. It is anticipated that functional data from BRCA1 and BRCA2 will soon be 
incorporated in this model[22,24,25[. 
The multifactorial likelihood method uses a number of different independent features 
in order to establish a combined likelihood estimate that a BRCA variant has the 
characteristics of known pathogenic variants[15[. The model currently combines the prior 
probability of variant pathogenicity (based on evolutionary conservation and amino acid 
physicochemical properties) with additional estimates of pathogenicity from likelihoods 
based on clinical information, including variant co-occurrence with a known pathogenic 
mutation in the same gene, tracking of the variant with cancer affected family members 
(segregation) and BRCA tumour features. The concept underlying multiparametric methods is 
that empiric probabilities that a person does have or does not have a pathogenic BRCA 
variant, can be established for each available line of evidence[20[. Multiple lines of evidence 
can be factored together as they become available in an iterative manner to produce an 
increasingly accurate probability of pathogenicity estimates for an individual variant. These 
estimates can be used to classify variants into clinically relevant strata (supplementary table 
T3)[18[. 
I-1b- Several classification systems have been proposed and there is no international 
consensus on which to adopt 
 A universal system for classification of variants common across all countries would 
facilitate education amongst new users of genetic tests and minimise the risk of 
misinterpretation. Unfortunately multiple systems have been proposed and are currently in 
use with many reporting laboratories not offering a clinically relevant classification. A World 
Health Organization-funded expert workshop at the International Agency for Research on 
Cancer (IARC) in 2008 recommended that the score from a multifactorial likelihood model is 
used to categorize high risk cancer gene variants[26,26[based on the multifactorial likelihood 
estimates of variant pathogenicity [18[. This is the only published classification system that 
links clinical recommendations to each class (supplementary table T3). The American 
College of Medical Genetics (ACMG) are recommending ClinVar as a common repository 
for genetic variants to help standardise reporting in the USA (supplementary table T4). 
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I-1c- Databases reporting genetic variants 
 A number of web-based resources catalogue variants reported in the BRCA1 and 2 
genes (supplementary table T4). For all variant databases, ongoing curation of deposited 
information, both at the time of deposition and reclassification, is a significant challenge. 
Some databases are actively curated while others rely heavily on the classification by the 
submitting laboratory with varying levels of supporting data provided. Also important is the 
use of standardized HGVS nomenclature (http://www.hgvs.org/) allowing unambiguous 
comparison of all data on the same variant in the database and across the literature. Apart 
from occasional national consortia, reporting of variants is not mandated so databases cannot 
usually be used to derive population frequencies of variants to aid classification (e.g. 
laboratories tend to underreport variants that have been found several times) and many do not 
catalogue the supporting evidence used to determine pathogenicity. A new attempt to collate 
BRCA VUS for the purpose of classication is the PROMPT registry (www.promptstudy.org). 
Patients receiving a BRCA VUS result are informed about the registry directly by the 
collaborating testing laboratory (including Myriad and Ambry Genetics) and/or their 
clinician. The patient can submit a range of medical information, genetic test report and 
tumour pathology reports and opt to participate in a variety of variant-specific research 
studies. 
 
Case 1. Two families were identified in separate countries with the same missense variant in 
BRCA1 designated c.5212G>A, NM_007294.3 (p.Gly1738Arg).  A number of women in 
both families were seeking risk-reducing surgery because of a strong family history of early 
age of onset of breast cancer in their families. The variant was a Class 3 (uncertain) variant 
(supplementary table T3) but it occurred at a highly conserved residue and it was recognised 
that more evidence may successfully confirm it was pathogenic. Predictive testing could then 
be offered to at risk family members to facilitate their preventive choices. Each family 
provided insufficient power for an informative segregation analysis but collaboration across 
centres in two countries with the same variant, allowed a segregation analysis to be 
completed and the VUS could then be re-classified as clearly pathogenic [27,27[.  It took a 
fortuitous academic collaboration and over 3 years to re-classify this VUS. The ENIGMA 
consortium[16[ provides a mechanism to rapidly link clinical teams looking after families 
with the same VUS to pool evidence. Segregation analyses will iteratively improve the 
estimations of the likelihood that each variant is pathogenic or not in a much more timely 
fashion. 
 
I-2- Pitfalls derived from frequency and population of origin of the VUS:  
 Rare variants (allele frequency <0.01) are usually not classifiable by an individual 
laboratory due to paucity of information and lack of statistical power. When the ethnicity of 
the patient being tested differs from the patient groups where most testing has been done, a 
sequence variant may have little publically available data and be rare in that laboratory so is 
more likely to be considered a VUS. 
Case 2: A 35 year old woman of African ancestry developed two primary breast tumours 
presenting at age 25 and 33. Both tumours were ER-, PR-, and Her2-.  She had no family 
history of cancer, but testing was initiated on the basis of her personal cancer history. She 
was found to have two VUS in BRCA1; variant 1, c.5154G>T, NM_007294.3 
(p.Trp1718Cys), and variant 2 in the 3’ UTR region, c.*36C>G, NM_007294.3.  DNA 
samples from relatives indicated that both variants are likely located on the same allele. 
Variant 2 is frequent (6-11%) in the African-American population[28,28[ and could be 
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assigned to Class 1 (non-pathogenic). Variant 1 involves amino acid substitution at a highly 
conserved residue predicted in silico to have a functional impact but could not then be 
classified unambiguously due to insufficient data. The clinical dilemma for this patient thus 
becomes whether the available information about variant 1 is sufficient to predict a high risk 
of ovarian cancer and recommend risk reducing bilateral salpingo-oophorectomy.  
A literature search identified two reports of variant 1. The first report was of 2 families from 
Asturias, Northern Spain[29[. Contact with the authors clarified the following details, some 
directly applicable for variant interpretation: Asturian proband 1 was diagnosed with bilateral 
invasive ductal breast cancer at age 28 (grade III, ER-) and 30 (grade II, ER -, PR -, HER2 –); 
Asturian proband 2 developed breast cancer at age 40 (ER and grade unknown), and probably 
also ovarian cancer at age 63. The second report of the variant was in an African American 
patient and family members where the variant was present in 4/4 women with cancer and 
absent in 3/3 at-risk women without cancer.  Pathogenicity was supported by the functional 
assay showing loss of transcriptional activity[30[.   
 
Using multifactorial likelihood analysis[23[ combining all currently available evidence: a 
prior probability of 0.81 based on Align-GVGD prediction[31[, and likelihood ratios based 
on additional information gained about breast tumour pathology (Spurdle et al, in press), the 
posterior probability of pathogenicity for the variant is 0.98 which places it in class 4. Thus 
sufficient evidence is now available to estimate a substantially raised ovarian cancer risk and 
permit a clinically sound recommendation of BSO to reduce ovarian cancer risk. 
 
II Why is genetic counselling around VUS complex? 
Although it is expected that most Class 3 variants will represent non-pathogenic variants, it is 
critical that we improve and accelerate clinical annotation and classification. 
II-1- Limited genetic literacy amongst clinical professionals 
Disclosure of a VUS result can test the skills of even highly experienced genetic counselling 
teams. There can be considerable variation in experience with molecular genetics and with 
clinical BRCA gene testing leading to diverse clinical management recommendations. This 
situation is compounded by complex and variable presentation of diagnostic reports from 
laboratories and limited genetic literacy amongst treating clinicians, and exacerbated further 
by the patient’s perception, prior experiences and beliefs.   
 
Case 3: A BRCA2 missense variant p.Thr3033Ile (c.9098C>T, NM_000059.3) was identified 
in a 53 year old woman with ovarian cancer and no family history of breast or ovarian cancer. 
A Class 3 report was issued as little supporting evidence was available. The managing 
clinician treated the variant as clinically significant and offered genetic testing to the patient’s 
daughter and sister. The patient’s sister did not carry the variant, but the daughter did. The 
daughter was given the same cancer risk management advice as a pathogenic variant carrier 
including risk-reducing surgery. Additional information from a BRCA2 functional assay was 
subsequently used to reclassify this variant to Class 2 (likely of no clinical significance)[32[. 
Cancer risk estimates for the daughter and sister should have been based on family history 
alone. Since there was no family history, testing in relatives could not even provide useful 
additional information about segregation. 
This case illustrates the need to ensure improved genetic literacy amongst non-genetics 
professionals ordering DNA tests, particularly the uncertainty around VUS results, the 
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implications of testing in other family members and the need for a clear pathway for referral 
to colleagues experienced in the interpretation and follow up of variant results[33[.    
 
II-2- Perceptions of cancer risks associated with VUS 
 A genetic test for a disease like breast cancer that uncovers a rare variant may lead to 
both patients and clinicians to think, “what is the chance this rare variant has nothing to do 
with this clinical presentation?” and convince themselves it cannot be coincidental. The 
decision to undertake preventive surgery is complex and patients are likely to have had 
personal and family experiences which may have strongly contributed to their risk 
management decision. Class 3 VUS reports discussed with counselees are too frequently 
inaccurately perceived typically leading to overestimation of cancer risks, adverse 
psychological outcomes and more radical medical decisions[34,35[. Furthermore, “almost the 
same large number of counselees with an unclassified variant decided to have preventive 
surgery as pathogenic mutation carriers”[36[.  
Case 4: A BRCA1 VUS was identified some years previously in a woman who developed 
breast cancer at the age of 45 in the setting of a strong family history of early onset breast and 
ovarian cancer. The family believed the variant must be the answer to the strong family 
history despite the inconclusive evidence. Several family members came forward for 
predictive genetic testing which they incorrectly believed was available. Genetic testing was 
repeated some years later and a clearly pathogenic large exonic deletion in BRCA1 was then 
identified on the opposite allele confirming irrefutably that the original VUS could not be 
pathogenic and demonstrating that new or optimised mutation screening approaches will 
uncover missed mutations in some families.  
This case illustrates the importance of understanding a “non-informative” or inconclusive test 
aimed at detecting a genetic predisposition to cancer. It is important to be aware that mutation 
testing is less than 100% sensitive and a negative BRCA test result does not exclude an 
underlying hereditary cause. BRCA1 or BRCA2 gene mutations only account for an estimated 
20-30% of familial clustering of breast cancer so cancer patients negative for a BRCA test but 
with a strong family history should be referred for specialist assessment and advice about risk 
management in the cancer genetics clinic. 
The testing clinician has a responsibility to ensure that the person being tested accurately 
understands the test result. A helpful starting point is to estimate the probability of a 
deleterious BRCA mutation given the family history and tumour characteristic[37[. It is worth 
bearing in mind that with a low a priori probability of finding a pathogenic variant, the most 
likely outcome from testing would be no pathogenic variant found, the second most likely 
outcome would be a VUS, and the least likely outcome a pathogenic variant. It is good 
practice before embarking on a BRCA gene test to discuss with the patient the likelihood of 
these possible outcomes. The test result must be interpreted in the context of the family 
history and clear guidelines should be agreed for referral of cases to a specialist genetic clinic 
(supplementary figure F2). Finally, the experience gathered with VUS in BRCA1/2 is 
relevant to developing ethical norms and policy issues, including duty to recontact patients, 
as cancer gene panel, exome and genome sequencing become increasingly commonplace[38]. 
Recommendations   
We believe some essential elements are necessary for the optimal clinical use and 
interpretation of VUS in mainstream medical practice.  
a) Variant reporting and classification 
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• An internationally accepted terminology and a clinically relevant classification to 
report and discuss BRCA test results.  
• A framework for clinicians, clinical scientists and research groups to work together 
towards classification of VUS.  
• Reporting of sequence variants to a single, transparently and expertly curated database 
providing clinically relevant classification for each reported BRCA variant based on 
clearly stated lines of evidence and freely available to all providers of genetic testing.   
 
b) Risk communication  
• Improve the genetics literacy of medical providers by structured training and 
integrating genomics into undergraduate, basic and specialist medical training 
curriculae.  
• Access and clear referral guidelines to specialist clinical genetics services for patients 
with a pathogenic variant, a VUS or a strong family history and no detectable genetic 
cause. 
• A close working relationship between genetic diagnostic laboratories, genetic 
specialists and cancer clinicians delivering an integrated care pathway for patients and 
their families. 
 
c) Data review 
• A Standard Operating Procedure within reporting laboratories to review variant 
classification each time new evidence emerges.  
• A clearly agreed process for reporting updated classifications (laboratories) and 
recontacting patients (clinicians) if a VUS becomes classified into clinically 
actionable or definitively non-pathogenic. 
 
Concluding remarks 
VUS identified in BRCA genes represent a major clinical challenge. Individuals with 
significant family history, a pathogenic variant or a VUS should be referred to a genetic 
specialist service. Patients with no pathogenic variant or a VUS should be managed based on 
the family history only. Standardised reporting and better genetic literacy must be 
implemented to safely introduce genetics into mainstream oncology. In conclusion, concerted 
action between the clinical and research communities is the best approach to optimally 
managing BRCA variants for maximum patient benefit. The international ENIGMA 
consortium is focussed on improving the interpretation of BRCA VUS and incorporates both 
clinical and research expertise.  Through a collaborative approach and a global and unified 
source of data and variant classification, important advances in this complex field will 
continue to benefit patients. 
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Abstract 
Background 
Increasing use of BRCA1/2 testing for tailoring cancer treatment and extension of testing 
to tumour tissue for somatic mutation is moving BRCA1/2 mutation screening from a 
primarily prevention arena delivered by specialist genetic services into mainstream oncology 
practice. A considerable number of gene tests will identify rare variants where clinical 
significance cannot be inferred from sequence information alone. The proportion of Variants 
of Uncertain clinical Significance (VUS) is likely to grow with lower thresholds for testing 
and laboratory providers with less experience of BRCA. Most VUS will not be associated 
with a high risk of cancer but a misinterpreted VUS has the potential to lead to 
mismanagement of both the patient and their relatives. 
  
Design 
Members of the Clinical Working Group of  ENIGMA (Evidence-based Network for 
the Interpretation of Germline Mutant Alleles) global consortium 
(www.enigmaconsortium.org) observed wide variation in practices in reporting, disclosure 
and clinical management of patients with a VUS. Examples from current clinical practice are 
presented and discussed to illustrate potential pitfalls, explore factors contributing to 
misinterpretation, and propose approaches to improving clarity. 
 
Results and conclusion 
Clinicians, patients and their relatives would all benefit from an improved level of 
genetic literacy. Genetic laboratories working with clinical geneticists need to agree on a 
clinically clear and uniform format for reporting BRCA test results to non-geneticists.  An 
international consortium of experts, collecting and integrating all available lines of evidence 
and classifying variants according to an internationally recognized system will facilitate 
reclassification of variants for clinical use.  
 
Key words: variants of uncertain significance, VUS, BRCA, clinical utility, classification 
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Introduction  
 Germline inactivating variants in the tumor suppressor genes BRCA1 and BRCA2 
confer high life time risks of breast cancer, ovarian cancer and less frequently also other 
cancers[1[[1]. These pathogenic variants are conventionally called ‘mutations’ or ‘deleterious 
variants’ in BRCA genetic testing parlance and the term pathogenic variant is used here for 
the sake of precision. Pathogenic variants in either gene confer a high lifetime risk of 
developing ovarian or (another) primary breast cancer in female carriers but they explain only 
about 20% of familial breast cancer[2[. The more cancers, the younger the onset and the 
admixture of ovarian with breast cancer amongst relatives all increase the chance that a 
familial cluster is due to a BRCA gene mutation but nonetheless most familial clusters of 
breast cancer are not due to an inherited mutation in BRCA1 or BRCA2.can be found in 
about 30% of multiple-case breast cancer families, but are also In addition to familial clusters 
the underlying cause inBRCA mutations account for over 10% of patients with early onset 
triple negative breast cancer and over 10% of women with non-mucinous ovarian cancer with 
no family history[3,4[[2,3]. Germline genetic testing for BRCA1 and BRCA2 for cancer risk 
prediction and management is delivered by clinical genetics professionals.  Female carriers 
with pathogenic variants who are still free of disease can make informed decisions about 
prophylactic surgery or intensified screening programs. High profile media coverage 
increases patient expectations from genetic testing[5,6[[4,5]. The indications for germline 
genetic testing for BRCA1 and BRCA2 are further increasing to include directing cancer 
chemotherapy, novel targeted treatments and informing choices about the extent of 
therapeutic surgery[7-9[[6-8].Germline genetic testing for BRCA1 and BRCA2 for cancer risk 
prediction and management is routinely delivered by clinical genetics professionals but 
increasing demand is overwhelming the current delivery model with insufficient capacity 
amongst trained geneticists and genetic counsellor. Safe i There are insufficient trained 
geneticists and genetic counsellors to meet the, therefore integration of genetic counselling 
with testinand testingg for HBOC into mainstream oncology is an ongoing challenge. 
Challenges exist at many levels but key are genetic literacy and genetic test outcome 
interpretation and reporting. 
 
Variability between individuals’ genetic code is common within the general population and 
between individuals of different ethnic background and this intrinsic variability can lead to 
difficulties in interpreting certain types of gsequence change (see supplementary figure 1 for 
more information). Currently, terms used in genetic test clinical reports vary (Supplementary 
table 1). Variants of uncertain clinical significance (VUS) including predicted missense 
alterations, in-frame deletions or insertions, and intronic variants outside of conserved splice 
site motifs, represent a particular challenge since the clinical significance cannot be inferred 
from sequence information alone. Mis-interpretation of VUS can lead to real clinical harms 
for both patients and families [10-12[[9-11].Furthermore terms used in genetic test clinical 
reports vary (see supplementary table 1). 
 
Approximately 5-15Up to 20 % of BRCA1/2 tests will report genetic variants of uncertain 
clinical significance (VUS) but in a well characterised ethnic population the proportion may 
drop to 5% or less[13,14[  [15[[12].The ENIGMA consortium has received over 6,000 
submissions of unique VUS, identified in over 13,000 families from over 17 
countries[16[[13]. Laboratories following generic reporting rules and with limited BRCA 
specific experience, may report more significance to variants in BRCA genes than is 
supported when multiple lines of evidence are taken into account[17[[14]. The percentage of 
gene-tests resulting in a VUS is expected to increase when the extent of sequencing increases 
to include untranslated and deeper intronic regions and when tumour testing is offered. We 
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restrict examples in this paper to the BRCA genes tested in blood samples but an additional 
challenge arises when genetic tests are sequencing lower penetrance genes on targeted gene 
panels. In lower penetrance genes, even unequivocally protein damaging variants have very 
different clinical implications compared to highly penetrant deleterious BRCA gene 
mutations.   
 
Members of the Evidence-based Network for the Interpretation of Germline Mutant Alleles 
(ENIGMA) consortium’s Clinical Working Group have collated real case scenarios from 
clinical practice to illustrate the pitfalls that can arise after a VUS test result and suggest some 
strategies to mitigate this risk. Clinicians who are requesting BRCA tests need to consider 
these issues when using BRCA test results in the management of patients and their families. 
 
I. The VUS report: why are VUS difficult to classify?   
 
I-1- Pitfalls associated with variability in the information content of genetic test reports 
 Based on the experience of representatives from 17 countries, it is clear that there is 
currently no internationally accepted standard for BRCA testing reporting (supplementary 
table 1), and no agreed consistent classification system: some laboratories report variants 
without interpretation, some use a narrative approach and some use locally developed 
guidelines or published schemes[18,19[[15,16]. For some types of BRCA gene variants, 
additional evidence may be essential before a variant can be clearly classified. Different lines 
of evidence may appear to conflict, so an integrated estimation of probability taking all 
available evidence into account is essential to reach a final classification for many 
variants[20,21[[17,18]. 
 
I-1a-Multiple lines of evidence may be required to establish pathogenicity 
 Software packages are available to help interpret genetic variants, each with strengths 
and weaknesses (supplementary table 2). Understanding of how the multiple functions of the 
BRCA1 and BRCA2 proteins relate to cancer predisposition is limited and few validated 
functional assays are available[22[[19]. The interpretation of functional studies is often 
technically complex and results may not be calibrated against clinical parameters in order to 
give measures of sensitivity and specificity. A major breakthrough in the field of BRCA 
variant classification has been the development of a multifactorial likelihood classification 
model[20,23[[17,20]. It is anticipated that functional data from BRCA1 and BRCA2 will 
soon be incorporated in this model[22,24,25[[19,21,22]. 
The multifactorial likelihood method uses a number of different independent features 
in order to establish a combined likelihood estimate that a BRCA variant has the 
characteristics of known pathogenic variants[15[[12[. The model currently combines the prior 
probability of variant pathogenicity (based on evolutionary conservation and amino acid 
physicochemical properties) with additional estimates of pathogenicity from likelihoods 
based on clinical information, including variant co-occurrence with a known pathogenic 
mutation in the same gene, tracking of the variant with cancer affected family members 
(segregation) and BRCA tumour features. The concept underlying multiparametric methods is 
that empiric probabilities that a person does have or does not have a pathogenic BRCA 
variant, can be established for each available line of evidence[20[[17[. Multiple lines of 
evidence can be factored together as they become available in an iterative manner to produce 
an increasingly accurate probability of pathogenicity estimates for an individual variant. 
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These estimates can be used to classify variants into clinically relevant strata (supplementary 
table 3)[18[[15]. 
I-1b- Several classification systems have been proposed and there is no international 
consensus on which to adopt 
 A universal system for classification of variants common across all countries would 
facilitate education amongst new users of genetic tests and minimise the risk of 
misinterpretation. Unfortunately multiple systems have been proposed and are currently in 
use with many reporting laboratories not offering a clinically relevant classification. A World 
Health Organization-funded expert workshop at the International Agency for Research on 
Cancer (IARC) in 2008 recommended that the score from a multifactorial likelihood model is 
used to categorize high risk cancer gene variants[26,26[[23,23]based on the multifactorial 
likelihood estimates of variant pathogenicity [18[[15]. This is the only published 
classification system that links clinical recommendations to each class (supplementary table 
3). The American College of Medical Genetics (ACMG) are recommending ClinVar as a 
common repository for genetic variants to help standardise reporting in the USA 
(Supplementary table 4). 
I-1c- Databases reporting genetic variants 
 A number of web-based resources catalogue variants reported in the BRCA1 and 2 
genes (supplementary table 4). For all variant databases, ongoing curation of deposited 
information, both at the time of deposition and reclassification, is a significant challenge. 
Some databases are actively curated while others rely heavily on the classification by the 
submitting laboratory with varying levels of supporting data provided. Also important is the 
use of standardized HGVS nomenclature (http://www.hgvs.org/) allowing unambiguous 
comparison of all data on the same variant in the database and across the literature. Apart 
from occasional national consortia, reporting of variants is not mandated so databases cannot 
usually be used to derive population frequencies of variants to aid classification (e.g. 
laboratories tend to underreport variants that have been found several times) and many do not 
catalogue the supporting evidence used to determine pathogenicity. A new attempt to collate 
BRCA VUS for the purpose of classication is the PROMPT registry (www.promptstudy.org). 
Patients receiving a BRCA VUS result are informed about the registry directly by the 
collaborating testing laboratory (including Myriad and Ambry Genetics) and/or their 
clinician. The patient can submit a range of medical information, genetic test report and 
tumour pathology reports and opt to participate in a variety of variant-specific research 
studies. 
 
Case 1. Two families were identified in separate countries with the same missense variant in 
BRCA1 designated c.5212G>A, NM_007294.3 (p.Gly1738Arg).  A number of women in 
both families were seeking risk-reducing surgery because of a strong family history of early 
age of onset of breast cancer in their families. The variant was a Class 3 (uncertain) variant 
(supplementary table 3) but it occurred at a highly conserved residue and it was recognised 
that more evidence may successfully confirm it was pathogenic. Predictive testing could then 
be offered to at risk family members to facilitate their preventive choices. Each family 
provided insufficient power for an informative segregation analysis but collaboration across 
centres in two countries with the same variant, allowed a segregation analysis to be 
completed and the VUS could then be re-classified as clearly pathogenic [27,27[[24,24].  It 
took a fortuitous academic collaboration and over 3 years to re-classify this VUS. The 
ENIGMA consortium[16[[13] provides a mechanism to rapidly link clinical teams looking 
after families with the same VUS to pool evidence. Segregation analyses will iteratively 
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improve the estimations of the likelihood that each variant is pathogenic or not in a much 
more timely fashion. 
 
I-2- Pitfalls derived from frequency and population of origin of the VUS:  
 Rare variants (allele frequency <0.01) are usually not classifiable by an individual 
laboratory due to paucity of information and lack of statistical power. When the ethnicity of 
the patient being tested differs from the patient groups where most testing has been done, a 
sequence variant may have little publically available data and be rare in that laboratory so is 
more likely to be considered a VUS. 
Case 2: A 35 year old woman of African ancestry developed two primary breast tumours 
presenting at age 25 and 33. Both tumours were ER-, PR-, and Her2-.  She had no family 
history of cancer, but testing was initiated on the basis of her personal cancer history. She 
was found to have two VUS in BRCA1; variant 1, c.5154G>T, NM_007294.3 (p.Trp1718Cys 
), and variant 2 in the 3’ UTR region, c.*36C>G, NM_007294.3.  DNA samples from 
relatives indicated that both variants are likely located on the same allele. Variant 2 is 
frequent (6-11%) in the African-American population[28,28[[25,25] and could be assigned to 
Class 1 (non-pathogenic). Variant 1 involves amino acid substitution at a highly conserved 
residue predicted in silico to have a functional impact but could not then be classified 
unambiguously due to insufficient data. The clinical dilemma for this patient thus becomes 
whether the available information about variant 1 is sufficient to predict a high risk of ovarian 
cancer and recommend risk reducing bilateral salpingo-oophorectomy.  
A literature search identified two reports of variant 1. The first report was of 2 families from 
Asturias, Northern Spain[29[[26]. Contact with the authors clarified the following details, 
some directly applicable for variant interpretation: Asturian proband 1 was diagnosed with 
bilateral invasive ductal breast cancer at age 28 (grade III, ER-) and 30 (grade II, ER -, PR -, 
HER2 –); Asturian proband 2 developed breast cancer at age 40 (ER and grade unknown), 
and probably also ovarian cancer at age 63. The second report of the variant was in an 
African American patient and family members where the variant was present in 4/4 women 
with cancer and absent in 3/3 at-risk women without cancer.  Pathogenicity was supported by 
the functional assay showing loss of transcriptional activity[30[[27].   
 
Using multifactorial likelihood analysis[23[[20] combining all currently available evidence: a 
prior probability of 0.81 based on Align-GVGD prediction[31[[28], and likelihood ratios 
based on additional information gained about breast tumour pathology (Spurdle et al, in 
press), the posterior probability of pathogenicity for the variant is 0.98 which places it in 
class 4. Thus sufficient evidence is now available to estimate a substantially raised ovarian 
cancer risk and permit a clinically sound recommendation of BSO to reduce ovarian cancer 
risk. 
 
II Why is genetic counselling around VUS complex? 
Although it is expected that most Class 3 variants will represent non-pathogenic variants, it is 
critical that we improve and accelerate clinical annotation and classification. 
II-1- Limited genetic literacy amongst clinical professionals 
Disclosure of a VUS result can test the skills of even highly experienced genetic counselling 
teams. There can be considerable variation in experience with molecular genetics and with 
clinical BRCA gene testing leading to diverse clinical management recommendations. This 
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situation is compounded by complex and variable presentation of diagnostic reports from 
laboratories and limited genetic literacy amongst treating clinicians, and exacerbated further 
by the patient’s perception, prior experiences and beliefs.   
 
Case 3: A BRCA2 missense variant p.Thr3033Ile (c.9098C>T, NM_000059.3) was identified 
in a 53 year old woman with ovarian cancer and no family history of breast or ovarian cancer. 
A Class 3 report was issued as little supporting evidence was available. The managing 
clinician treated the variant as clinically significant and offered genetic testing to the patient’s 
daughter and sister. The patient’s sister did not carry the variant, but the daughter did. The 
daughter was given the same cancer risk management advice as a pathogenic variant carrier 
including risk-reducing surgery. Additional information from a BRCA2 functional assay was 
subsequently used to reclassify this variant to Class 2 (likely of no clinical 
significance)[32[[29]. Cancer risk estimates for the daughter and sister should have been 
based on family history alone. Since there was no family history, testing in relatives could not 
even provide useful additional information about segregation. 
This case illustrates the need to ensure improved genetic literacy amongst non-genetics 
professionals ordering DNA tests, particularly the uncertainty around VUS results, the 
implications of testing in other family members and the need for a clear pathway for referral 
to colleagues experienced in the interpretation and follow up of variant results[33[[30].    
 
II-2- Perceptions of cancer risks associated with VUS 
 A genetic test for a disease like breast cancer that uncovers a rare variant may lead to 
both patients and clinicians to think, “what is the chance this rare variant has nothing to do 
with this clinical presentation?” and convince themselves it cannot be coincidental. The 
decision to undertake preventive surgery is complex and patients are likely to have had 
personal and family experiences which may have strongly contributed to their risk 
management decision. Class 3 VUS reports discussed with counselees are too frequently 
inaccurately perceived typically leading to overestimation of cancer risks, adverse 
psychological outcomes and more radical medical decisions[34,35[[31,32]. Furthermore, 
“almost the same large number of counselees with an unclassified variant decided to have 
preventive surgery as pathogenic mutation carriers”[36[[33].  
Case 4: A BRCA1 VUS was identified some years previously in a woman who developed 
breast cancer at the age of 45 in the setting of a strong family history of early onset breast and 
ovarian cancer. The family believed the variant must be the answer to the strong family 
history despite the inconclusive evidence. Several family members came forward for 
predictive genetic testing which they incorrectly believed was available. Genetic testing was 
repeated some years later and a clearly pathogenic large exonic deletion in BRCA1 was then 
identified on the opposite allele confirming irrefutably that the original VUS could not be 
pathogenic and demonstrating that new or optimised mutation screening approaches will 
uncover missed mutations in some families.  
This case illustrates the importance of understanding a “non-informative” or inconclusive test 
aimed at detecting a genetic predisposition to cancer. It is important to be aware that mutation 
testing is less than 100% sensitive and a negative BRCA test result does not exclude an 
underlying hereditary cause. BRCA1 or BRCA2 gene mutations only account for an estimated 
20-30% of familial clustering of breast cancer so cancer patients negative for a BRCA test but 
with a strong family history should be referred for specialist assessment and advice about risk 
management in the cancer genetics clinic. 
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The testing clinician has a responsibility to ensure that the person being tested accurately 
understands the test result. A helpful starting point is to estimate the probability of a 
deleterious BRCA mutation given the family history and tumour characteristic[37[[34]. It is 
worth bearing in mind that with a low a priori probability of finding a pathogenic variant, the 
most likely outcome from testing would be no pathogenic variant found, the second most 
likely outcome would be a VUS, and the least likely outcome a pathogenic variant. It is good 
practice before embarking on a BRCA gene test to discuss with the patient the likelihood of 
these possible outcomes. The test result must be interpreted in the context of the family 
history and clear guidelines should be agreed for referral of cases to a specialist genetic clinic 
(supplementary figure 1F2). Finally, the experience gathered with VUS in BRCA1/2 is 
relevant to developing ethical norms and policy issues, including duty to recontact patients, 
as cancer gene panel, exome and genome sequencing become increasingly commonplace[38]. 
Recommendations   
We believe some essential elements are necessary for the optimal clinical use and 
interpretation of VUS in mainstream medical practice.  
a) Variant reporting and classification 
• An internationally accepted terminology and a clinically relevant classification to 
report and discuss BRCA test results.  
• A framework for clinicians, clinical scientists and research groups to work together 
towards classification of VUS.  
• Reporting of sequence variants to a single, transparently and expertly curated database 
providing clinically relevant classification for each reported BRCA variant based on 
clearly stated lines of evidence and freely available to all providers of genetic testing.   
 
b) Risk communication  
• Improve the genetics literacy of medical providers by structured training and 
integrating genomics into undergraduate, basic and specialist medical training 
curriculae.  
• Access and clear referral guidelines to specialist clinical genetics services for patients 
with a pathogenic variant, a VUS or a strong family history and no detectable genetic 
cause. 
• A close working relationship between genetic diagnostic laboratories, genetic 
specialists and cancer clinicians delivering an integrated care pathway for patients and 
their families. 
 
c) Data review 
• A Standard Operating Procedure within reporting laboratories to review variant 
classification each time new evidence emerges.  
• A clearly agreed process for reporting updated classifications (laboratories) and 
recontacting patients (clinicians) if a VUS becomes classified into clinically 
actionable or definitively non-pathogenic. 
 
Concluding remarks 
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VUS identified in BRCA genes represent a major clinical challenge. Individuals with 
significant family history, a pathogenic variant or a VUS should be referred to a genetic 
specialist service. Patients with no pathogenic variant or a VUS should be managed based on 
the family history only. Standardised reporting and better genetic literacy must be 
implemented to safely introduce genetics into mainstream oncology. In conclusion, concerted 
action between the clinical and research communities is the best approach to optimally 
managing BRCA variants for maximum patient benefit. The international ENIGMA 
consortium is focussed on improving the interpretation of BRCA VUS and incorporates both 
clinical and research expertise.  Through a collaborative approach and a global and unified 
source of data and variant classification, important advances in this complex field will 
continue to benefit patients. 
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Supplementary material: 
Supplementary figure 1: Genetic variability information 
 
Supplementary figure 2: Suggested clinical pathway for patients when genetic testing is 
initiated  by the oncology clinic. 
 
Supplementary table (1).  Types of sequence variants reported in BRCA mutation detection 
tests according to risk relevant for clinical management 
 
Supplementary table (2). Examples of software tools available for clinical variant evaluation 
online 
 
Supplementary table 3. 5-tier classification BRCA1/2 VUS 
 
Supplementary table 4. Commonly used online database resources that provide some 
interpretation of BRCA sequence variants  
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Supplementary Table (1).  Types of sequence variants reported in BRCA mutation detection tests  
according to  risk relevant for clinical management 
Clinical risk Descriptors observed in clinical 
reports  
Interpretation 
High • Functionally deleterious 
mutation 
• Pathogenic mutation 
• High risk mutation 
• Deleterious variant 
 
Variants that result in a high lifetime risk of 
breast and ovarian cancer. Deleterious 
variants disrupt normal protein function. 
They include nonsense changes, out-of-
frame insertions or deletions, large gene 
rearrangements or splicing variants altering 
the canonical splicing acceptor and donor 
sites disrupting regulatory regions, as well as 
some missense changes. Supportive 
evidence from multiple sources may be 
required to call a variant deleterious where 
predictions of functional consequences are 
unclear
a
. 
Uncertain • Missense mutation 
• Rare variant 
• Variant of uncertain clinical 
significance (VUS, VOUS) 
• Uncertain Variant 
• Variant of Uncertain  
• Variant of Unknown Clinical 
Significance 
Variants that differ from the published 
reference DNA sequence (RefSeq BRCA1: 
U14680; BRCA2: NM00059) and are not 
classifiable as either deleterious or as 
neutral based on available evidence.   
The association with clinical phenotype at 
this time is unknown and cannot be used to 
inform clinical decisions. 
None • Frequent mutation 
• Common variant 
• Polymorphism 
• Variants of low clinical 
significance 
• Variants of no clinical 
significance 
• Neutral variants 
• Benign variants 
Changes in the DNA sequence that do not 
disrupt the normal function of the encoded 
protein and are not associated with a 
clinically important increased risk of disease. 
If present in the population at a frequency of 
greater than 1% these may be referred to as 
polymorphisms. 
a
 for example assays showing partial loss of normal transcript from aberrant splicing or partially 
reduced function from an amino acid substitution may require additional evidence to classify as 
class 4 or 5. 
 
 
Page 34 of 40Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Supplementary Table (2) Examples of software tools available for clinical variant evaluation online 
Resource  Description Website 
Polyphen2 POLYmorphism PHENotypes 
Polyphen2 is freely available, web-based 
program from Harvard University that predicts 
whether an amino acid substitution affects 
protein structure and function. 
http://genetics.bwh.harvard.edu/pph2/  
SIFT Sorting Intolerant From Tolerant 
SIFT software is freely available and predicts 
whether an amino acid substitution affects 
protein function. 
http://sift.jcvi.org/  
Align-GVGD  
 
Align Grantham Variation and Grantham 
Deviation. 
Align-GVGD is a freely available, web-based 
program from IARC (International Agency for 
Cancer Research) that combines the known 
chemical nature of amino acids and the 
alignments of DNA sequences across species to 
predict the likely pathogenicity of missense 
substitutions.  
http://agvgd.iarc.fr/about.php   
HCI 
database of 
prior 
probabilities  
The Huntsman Cancer Institute Database of Prior 
Probabilities of Pathogenicity for Single 
Nucleotide Substitutions provides the prior 
probability of pathogenicity estimate which is the 
starting point for the multifactorial likelihood 
estimate for a novel SNP identified through 
genetic testing for a BRCA gene. 
http://priors.hci.utah.edu/PRIORS/ 
 
 
GeneSplicer  GeneSplicer is a freely available flexible system 
for detecting splice sites in the genomic DNA of 
various eukaryotes. 
http://www.ncbi.nlm.nih.gov/pmc/article
s/PMC29713/ 
Human 
Splicing 
Finder 
This tool is freely available and aimed at studying 
pre-mRNA splicing and identifying variants that 
may disrupt normal splicing.  
http://www.umd.be/HSF3/  
Commercial 
software e.g. 
Alamut 
Alamut is commercially available software that 
provides a single interface to bring  together 
multiple data sources including many of those 
listed above in a simplified and streamlined tool 
for rapid assembly of data about any one variant 
aimed at busy diagnostic laboratories.  
http://www.interactivebiosoftware.com/s
oftware/alamut/overview  
Entrez-
Pubmed 
Google 
Scholar 
Web-based search engines to look for research 
publications including a specific mutation. 
http://www.ncbi.nlm.nih.gov/pubmed  
http://scholar.google.com 
UMD-BRCA1 
UMD-BRCA2 
The UMD-BRCA1/BRCA2 databases have been set 
up in a joined national effort through the 
network of the 16 French diagnostic laboratories. 
A classification is proposed based on the classical 
parameters including splicing algorithms. A 
strong effort is done to perform cosegregation 
studies. 
http://www.umd.be/BRCA1/ 
http://www.umd.be/BRCA2/ 
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Supplementary  Table 3. 5-tier classification BRCA1/2 VUS modified from [15]  
Class Description Probability 
of being 
pathogenic 
Clinical 
predictive 
testing of at 
risk relatives 
Management 
recommendations if at-
risk relative has the 
variant 
Research 
testing of 
family 
members 
5 Definitely 
pathogenic 
>0.99 Yes Full high-risk guidelines Not 
indicated 
4 Likely 
pathogenic 
0.95-0.99 Yes Full high-risk guidelines May be 
helpful to 
further 
classify 
variant 
3 Uncertain 0.05-0.949 No Presence of variant is 
irrelevant to risk 
assessment, manage risk 
based on family history 
only  
May be 
helpful to 
further 
classify 
variant 
2 Likely not 
pathogenic or 
of no clinical 
significance 
0.001-0.049 No Manage risk based on 
family history only 
May be 
helpful to 
further 
classify 
variant 
1 Not pathogenic 
or of no clinical 
significance 
<0.001 No Manage risk based on 
family history only 
Not 
indicated 
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Supplementary Table 4: Commonly used online database resources that provide some interpretation 
of BRCA sequence variants although  
Resource  Description Website 
IARC/LOVD – 
(Leiden Open 
(source) 
Variation 
Database) 
Separate BRCA1 and BRCA2 variant databases 
curated by experts at the University of Leiden 
and IARC. Includes only those VUS with literature 
references and records the published literature 
associated which each variant. Each variant is 
given an IARC class[15] and links to published 
source data. Submissions of variants are from 
registered submitters largely from the research 
community. Curation of submissions for each 
gene is undertaken by a named expert curator on 
a voluntary basis. 
http://brca.iarc.fr/LOVD/home.php  
soon to be replaced by 
http://hci-
exlovd.hci.utah.edu/home.php 
The Breast 
Cancer 
Information 
Core (BIC)  
A database that acts as a central repository for 
BRCA1 and BRCA2 variants (deleterious, neutral 
or VUS) deposited by submitters from research 
and clinical sites internationally. Recently, a 
central curation process working to classify all 
variants according to the IARC 5 tier 
classification[15] scheme has been introduced. 
http://research.nhgri.nih.gov/bic 
ClinVar ClinVar is a freely accessible, public archive of 
reports of the relationships between human 
variations and phenotypes presented with 
supporting evidence and an indication of likely 
clinical significance. Submissions are from 
research and some diagnostic laboratories and 
submitters include a classification for submitted 
variants, submissions are not currently curated. 
http://www.ncbi.nlm.nih.gov/clinvar/  
Human Variome 
Project 
 
The Human Variome Project, under the auspices 
of UNESCO, has been created as a unified 
reporting portal and lists 4 separate databases 
for BRCA1 and 4 for BRCA2. As yet it offers no 
formal curation or attempt to classify variants  
http://www.humanvariomeproject.org 
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Supplementary Table 4: Commonly used online database resources that provide some interpretation 
of BRCA sequence variants  
Resource  Description Website 
IARC/LOVD – 
(Leiden Open 
(source) 
Variation 
Database) 
Separate BRCA1 and BRCA2 variant databases 
curated by experts at the University of Leiden 
and IARC. Includes only those VUS with literature 
references and records the published literature 
associated which each variant. Each variant is 
given an IARC class[15[ and links to published 
source data. Submissions of variants are from 
registered submitters largely from the research 
community. Curation of submissions for each 
gene is undertaken by a named expert curator on 
a voluntary basis. 
http://brca.iarc.fr/LOVD/home.php  
soon to be replaced by 
http://hci-
exlovd.hci.utah.edu/home.php 
The Breast 
Cancer 
Information 
Core (BIC)  
A database that acts as a central repository for 
BRCA1 and BRCA2  variants (deleterious, neutral 
or VUS) deposited by submitters from research 
and clinical sites internationally. Recently, a 
central curation process working to classify all 
variants according to the IARC 5 tier 
classification[15] scheme has been introduced.An 
international collaboration that acts as a central 
repository for all reported BRCA1 and BRCA2  
deleterious, neutral and VUS variants. The vast 
majority of classifications are self-reported by 
the submitting laboratories. Recently, a central 
curation process working to classify all variants 
according to the IARC classification[15[ scheme 
has been introduced. 
http://research.nhgri.nih.gov/bic 
ClinVar ClinVar is a freely accessible, public archive of 
reports of the relationships between human 
variations and phenotypes presented with 
supporting evidence and an indication of likely 
clinical significance. Submissions are from 
research and some diagnostic laboratories and 
submitters include a classification for submitted 
variants, submissions are not currently curated. 
http://www.ncbi.nlm.nih.gov/clinvar/ 
Human Variome 
Project 
 
The Human Variome Project, under the auspices 
of UNESCO, has been created as a unified 
reporting portal and lists 4 separate databases 
for BRCA1 and 4 for BRCA2. As yet it offers no 
formal curation or attempt to classify variants  
http://www.humanvariomeproject.org 
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Figure 1: Important facts about genetic variability 
Variation in DNA is common 
Facts and terms Further information 
When a gene is tested for mutations, 
the sequence of that gene in the 
individual is compared to an accepted 
reference sequence for the gene and 
variation from the reference sequence 
is often observed. 
The human genome contains ~ 6 billion bases of genetic sequence 
in any diploid cell and on average there is a change in the 
reference sequence approximately every 500 bases, much of this 
variation does not obviously impact on function but occasionally it 
does. 
BRCA1 and BRCA2 are very large genes Random variation in the reference sequence occurs frequently 
across the population, not associated with any clinical effect. This 
is true whether the individual has had cancer or not. 
Non-pathogenic variation in sequence 
is as frequent in the general population 
as in the cancer affected patient 
It is tempting to believe that because a person with cancer has 
been tested for a mutation in the BRCA1/2 gene, that any 
deviation from the expected code is causative but in reality, in the 
absence of clear evidence of a loss of function in the mutated copy 
of the gene, most of the genetic variation is of little or no 
significance in relation to disease causation 
Different ethnic groups have different 
frequencies of variants 
For ethnic populations where relatively little genetic testing has 
been undertaken, common polymorphisms in that ethnic minority 
group may be unrecognised in the testing laboratory and are 
therefore more likely to be reported as of uncertain significance 
(VUS).  
Terms used in describing genetic variants 
Polymorphisms (meaning “many 
forms”) are common variations 
observed in more than 1% of the 
normal population. 
When observed frequently in population controls (unaffected by 
cancer), this type of sequence change is generally not associated 
with a high cancer risk.  
A change in a single base (T,G,A or C) is 
a single nucleotide variant and if the 
particular variant is relatively 
frequently observed in a particular  
population, it is called a single 
nucleotide polymorphism (SNP) 
Single nucleotide variants usually have no major clinical 
consequence especially if frequent (i.e. SNPs) but rarely they may 
affect the function of the protein being coded.  
Synonymous: a single base change in the exon which results in no 
change to the expected amino acid at that position so is usually of 
no consequence but can create or destroy a native donor or 
acceptor splice site. 
Non-synonymous: also known as missense mutations lead to a 
change in one amino acid, these may affect a critical functional 
domain, although most do not. 
Variants within an intron (ie non coding part of the gene) can also 
rarely destroy or create false donor or acceptor splice sites.  
 
In-frame deletions or insertions An insertion or deletion of three bases starting with the first base 
of an amino acid code is an in frame deletion or insertion and 
leads to the insertion or deletion of one or sometimes more  
amino acids but the full length protein is otherwise predicted to be 
complete. These may have no effect on protein function since 
most of the protein is translated correctly.  
Variants of uncertain significance (VUS) Where a change to the expected sequence is observed that has 
not been observed with any frequency in the testing laboratory 
and has not been classed as non-pathogenic in literature or 
databases, genetic testing laboratories will usually report these as 
a VUS. Gathering multiple lines of additional information may help 
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to clarify pathogenicity [15]. In reality most of these are unlikely to 
be pathogenic mutations but a few will be. 
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Recommendations for referral of cases to a specialist genetic clinic  
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